PAVmed (PAVM) EBITDA (2016 - 2026)

PAVmed has reported EBITDA for 11 years, with the latest figure at -$7.0 million in Q2 2026.

• On a quarterly basis, EBITDA fell 48.93% year-over-year to -$7.0 million in Q2 2026; TTM through Jun 2026 was -$23.4 million, a 19.45% increase from a year earlier, with the FY2025 full-year figure at -$21.8 million, up 50.98% from the prior year.
• EBITDA was -$7.0 million for Q2 2026 at PAVmed, down from -$6.8 million in the prior quarter.
• The five-year high for EBITDA was -$4.7 million in Q2 2025, with the low at -$24.6 million in Q4 2022.
• Average EBITDA over 5 years is -$13.9 million, with a median of -$14.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA tumbled 143.1% in 2022, then soared 68.34% in 2024.
• Over 5 years, EBITDA stood at -$24.6 million in 2022, then jumped by 33.41% to -$16.4 million in 2023, then jumped by 68.34% to -$5.2 million in 2024, then plunged by 31.15% to -$6.8 million in 2025, then dropped by 3.22% to -$7.0 million in 2026.
• The last three EBITDA figures came in at -$7.0 million (Q2 2026), -$6.8 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.